Eli Lilly: agreement to purchase a Nexus plant in the USA
The acquisition of this FDA-approved facility, located in Pleasant Prairie (Wisconsin, USA), will further expand Eli Lilly's global manufacturing network for parenteral (injectable) products and support increased demand for the company's medicines.
According to Eli Lilly, production at this facility could begin in late 2025.
' We are investing boldly to serve our patients, to meet product demand and to build capacity for our robust pipeline of the future', emphasized Edgardo Hernandez, Executive Vice President and President of Manufacturing at Eli Lilly.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction